Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


Purpose:

This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.


Criteria:

Inclusion Criteria - Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube cancer or primary peritoneal cancer - Recurrent epithelial ovarian cancer or persistent disease following primary treatment - At least one, but no more than four, prior platinum-containing chemotherapy regimens - At least one prior taxane-containing regimen Exclusion Criteria - A history of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which the patient has been disease-free for 2 years - Known leptomeningeal metastases or carcinomatous meningitis - Have received prior Doxil or other liposomal doxorubicin - Having received whole pelvis radiation therapy


NCT ID:

NCT00052065


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Houston, Texas 77030
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 12, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.